Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting

• Anders Svenningsson ,

  * E-mail: anders.svenningsson@neuro.umu.se

  Affiliation Dept of Pharmacology and Clinical Neuroscience, Umeå University and University Hospital of Northern Sweden, Umeå, Sweden

  ⨯
• Eva Falk,

  Affiliation BiogenIdec Sweden AB, Upplands Väsby, Sweden

  ⨯
• Elisabeth G. Celius,

  Affiliation Department of Neurology, Oslo University Hospital, Ullevål, Norway

  ⨯
• Siegrid Fuchs,

  Affiliation Department of Neurology, University of Graz, Graz, Austria

  ⨯
• Karen Schreiber,

  Affiliation Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

  ⨯
• Sara Berkö,

  Affiliation BiogenIdec Sweden AB, Upplands Väsby, Sweden

  ⨯
• Jennifer Sun,

  Affiliation BiogenIdec Global Medical Affairs, Boston, Massachusetts, United States of America

  ⨯
• Iris-Katharina Penner,

  Affiliation Department of Cognitive Psychology and Methodology, University of Basel, Basel, Switzerland

  ⨯
• for the TYNERGY trial investigators

  ¶Investigators of the TYNERGY trial are listed in the Acknowledgments.

  ⨯